Stem Cell Study for Patients With Leg Ulcer/Gangrene

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-11-30

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if stem cell therapy with one's own cells (autologous cells) delivered intramuscularly to one's leg with ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain, increase blood flow, and/or cure the leg wound.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer

NCT06231771

Diabetic Foot Ulcer

NOT_YET_RECRUITING PHASE1/PHASE2

Utilization of Platelet Gel for Treatment of Diabetic Foot Ulcers

NCT02134132

Diabetic Foot Ulcers

COMPLETED PHASE1/PHASE2

PRG Combined With Autologous BMMSCs for Treatment of Diabetic Foot Ulcer

NCT03248466

Diabetic Foot Ulcer

UNKNOWN EARLY_PHASE1

Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs

NCT02866565

Diabetic Foot Ulcer

NOT_YET_RECRUITING PHASE2

Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers

NCT04267640

Peripheral Artery Disease Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease Chronic Limb Threatening Ischemia +1 more

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic critical limb ischemia (CLI) is a progressive disease, which arises as a result of atherosclerosis or vasculitis in leg arteries. Prognosis of chronic CLI is poor, and no effective treatments have been established in patients who are not eligible for the traditional revascularization therapies such as angioplasty and bypass procedures due to the inappropriate anatomy of the leg arteries or frequent reocclusion following revascularization. Therefore, it is necessary to establish novel revascularization treatment to improve prognosis of the no-option patients. We will study the safety and clinical efficiency of vascular regeneration by means of transplantation of autologous peripheral blood endothelial progenitor cells (CD34 positive cells) in patients with chronic CLI who are not eligible for traditional revascularization treatments. The primary endpoint is the primary efficacy score identified by toe brachial blood pressure index (TBPI), absolute claudication distance (ACD) and Wong Baker's pain rating scale, while the secondary endpoints are evaluation of safety, ankle brachial blood pressure index (ABPI), percutaneous tissue oxygen pressure (TcPO2), etc.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leg Pain Ulcer Gangrene Ischemia Peripheral Vascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous peripheral blood CD34 positive cell therapy

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic severe CLI patients fulfilling all the following criteria are considered suitable for inclusion in the study.

1. At least 6 months since the onset of CLI (Chronic peripheral artery disease or Buerger disease)
2. Patients with luminal stenosis \> 50% by leg angiography
3. Age is between 20 and 80.
4. Patients whose Rutherford's class is II-4, III-5, or III-6（Patients with rest pain or ischemic ulcer/necrosis)
5. Patients for whom angioplasty and bypass surgery are not indicated because of anatomical or procedural reasons or frequent reocclusion/ restenosis following the traditional revascularization (No option patients)
6. Patients who can give informed consent themselves in writing.

Exclusion Criteria

1. Left ventricular ejection fraction \< 25%
2. Patients with a history of severe allergic reactions or side effects to G-CSF preparations or apheresis.
3. Less than 6 months since last episode of myocardial/cerebral infarction.
4. Patients with unstable angina, with a treatment rating of 3 in the Braunwald system, but a severity of III and a clinical rating of B or C.
5. Patients with diabetic proliferating retinopathy (new Fukuda classification BI to BV).
6. Patients with malignant tumor
7. Patients with chronic rheumatoid arthritis.
8. Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes).
9. Patients currently suffering from or having a history of interstitial pneumonitis.
10. Patients for whom cranial MRA reveals cerebral aneurysm.
11. Patients for whom abdominal CT or ultrasonography reveals splenomegaly.
12. Patients with cirrhosis of the liver.
13. Patients who cannot discontinue Warfarin.
14. Leukocytes less than 4,000/µL or exceeding 10,000/µL.
15. Platelets less than 100,000/µL.
16. Hemoglobin less than 10 g/dL.
17. AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.
18. Patients with severe neural disorder in their legs.
19. Patients with gait disturbance for reasons other than CLI (such as sciatic neuralgia, or vasculitis), making exercise tolerance evaluation on a treadmill with stress ECG difficult.
20. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period.
21. Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No